Skip to content
Published studies and FDA documents are linked throughout.
Doctor CJC-1295

CJC-1295 findings set down carefully. No practice runs here.

Menu
An empty blue swimming lane beside pale concrete in early light
A washed-blue towel folded on a wet timber bench

CJC-1295 and how it extends a hormone signal

A closer look at a long-acting peptide, the findings in people, and the questions those findings leave open.

Explore the research

Understanding CJC-1295

CJC-1295 was developed to stimulate growth hormone release. The long-acting version attaches to albumin, a protein in blood, which helps it remain in circulation. That longer exposure is the central finding behind its name. It is also why the exact form matters.

This guide follows the human research, then separates measured hormone changes from claims about everyday health. CJC-1295 has no FDA-approved medical use. The early studies leave substantial questions about benefits and long-term safety.

Three adults with towels over their shoulders walking along a pool deck toward the changing rooms, seen from behindResearch

What the human studies measured, and what remains unknown.

An adult stretching an arm on an outdoor terrace, viewed from behindEffects

Hormone responses, proposed benefits, and safety concerns.

Empty starting blocks at the end of the pool lanes, a blue towel over oneQuestions

The distinctions behind the names, approval, and sport rules.

An adult seated beside the pool after a morning swim, seen from behind

What the human studies measured

Small studies in healthy adults measured hormone changes, drug persistence, and short-term tolerability. A separate report examined hormone pulses.

Explore the study findings
A bed just left in the morning, white linen thrown back in early window light

The outcomes

These findings do not establish better sleep, less fat, or faster recovery. A changed hormone signal is a narrower outcome than improved health.

Read about effects

How CJC-1295 works

Growth hormone-releasing hormone, or GHRH, normally signals the pituitary gland to release growth hormone. CJC-1295 is a synthetic version designed to act on that signaling system. Growth hormone then influences insulin-like growth factor 1, usually shortened to IGF-1.

The DAC addition lets the peptide bind albumin. In early research in healthy adults, this form produced hormone changes lasting several days. A result for that long-acting form cannot simply be applied to a product described as no-DAC.

Understand the DAC form

How to read a CJC-1295 finding

The form, the participants, the outcome, and the observation period all matter. A study in healthy adults answers a different question from a trial in people with a diagnosed condition. A hormone measurement answers a different question from a change in symptoms.

FDA's assessment of CJC-1295 brings those limits together with concerns about immune reactions and other adverse effects. Small studies cannot settle risks that may appear after prolonged exposure.

A shaded club terrace with empty seating and a narrow strip of morning light

The form

DAC and no-DAC are different ingredients.

The participants

Healthy volunteers do not represent every patient.

The outcome

A hormone change is not a symptom improvement.

The time

Short follow-up leaves long-term questions.

A longer signal is one finding. What it means for health still needs evidence.

Use the research page for the study record, the effects page for benefits and harms, and the dosage page for what researchers administered. The questions page covers names, approval, and sport. Each keeps the difference between a measured response and a useful treatment visible.